COMPANY NEWS


Zydus Lifesciences Ltd
BSE Code 532321 ISIN Demat INE010B01027 Book Value (₹) 215.08 NSE Symbol ZYDUSLIFE Div & Yield % 1.18 Market Cap ( Cr.) 93,484.17 P/E * 19.37 EPS * 47.96 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Zydus Lifesciences receives USFDA tentative approval for Diroximel Fumarate Delayed-Release Capsules Back
(10 Jul 2024)

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Diroximel Fumarate Delayed-Release Capsules, 231 mg (USRLD: Vumerity® Delayed-Release Capsulestablets).

Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, India.

Diroximel Fumarate Delayed-Release Capsules had annual sales of USD 847.4 mn in the United States (IQVIA MAT May 2024).